# Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma

**Authors:** Vimala Anthonydhason, Erna Islamagic, Nikki Leijon, Jennie Gaarder, Tommy Martinsson, Susanne Fransson, Fredrik B Thorén, Ganesh Umapathy

PMC · DOI: 10.3389/fimmu.2026.1739503 · Frontiers in Immunology · 2026-02-10

## TL;DR

Inducing ferroptosis with Erastin boosts natural killer cell activity against neuroblastoma, a hard-to-treat childhood cancer.

## Contribution

This study reveals that Erastin-induced ferroptosis enhances NK cell anti-tumor activity in neuroblastoma via ULBP1 upregulation.

## Key findings

- Erastin reduces neuroblastoma cell proliferation and foci formation through ferroptosis induction.
- Erastin treatment increases ULBP1 expression in neuroblastoma cells, which activates natural killer cells.
- The transcription factor ATF4 mediates ULBP1 upregulation during ferroptosis, enhancing NK cell cytotoxicity.

## Abstract

High-risk neuroblastoma (NB) often relapses and becomes refractory to treatment, making it a significant contributor to childhood cancer mortality despite its relative rarity. Addressing the challenges posed by NB’s resistance to conventional apoptosis-inducing therapies (e.g., chemotherapy and radiation) has become a pressing concern in pediatric oncology research. In recent years, the growing comprehension of alternative cell death modalities distinct from apoptosis has revealed a promising avenue in the endeavor to combat treatment-resistant cancers. One such mechanism, ferroptosis, has attracted increasing attention for its potential role in combating therapy-resistant cancer cells. High-risk NB typically exhibits an immune-excluded phenotype, characterized by minimal immune cell infiltration. Despite this characteristic, the mechanisms underlying immune exclusion and impaired immune activation in NB remain unclear. Here, we demonstrate that the induction of ferroptosis using Erastin, a cystine-glutamate antiporter inhibitor, reduces NB cell proliferation and foci formation. Furthermore, our transcriptomics analysis revealed that treatment with Erastin in NB cells led to increased expression of ULBP1, a ligand to the activating natural killer (NK) cell receptor, NKG2D. Upon ferroptosis induction, the transcription factor ATF4 was found to drive ULBP1 expression in NB cells. Consistent with this, pre-treatment with Erastin sensitized NB cells to NK cell cytotoxicity in co-culture experiments. These results suggest the NK cell’s cytotoxic function can be enhanced with Erastin-mediated ferroptosis, which may be beneficial for NB patients.

## Linked entities

- **Genes:** ULBP1 (UL16 binding protein 1) [NCBI Gene 80329], ATF4 (activating transcription factor 4) [NCBI Gene 468], KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914]
- **Chemicals:** Erastin (PubChem CID 11214940)
- **Diseases:** neuroblastoma (MONDO:0005072)

## Full-text entities

- **Genes:** PHGDH (phosphoglycerate dehydrogenase) [NCBI Gene 26227] {aka 3-PGDH, 3PGDH, HEL-S-113, NLS, NLS1, PDG}, PSAT1 (phosphoserine aminotransferase 1) [NCBI Gene 29968] {aka EPIP, NLS2, PSA, PSAT, PSATD}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, MICA (MHC class I polypeptide-related sequence A) [NCBI Gene 100507436] {aka MIC-A, PERB11.1}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 482978] {aka N-MYC1}, ULBP3 (UL16 binding protein 3) [NCBI Gene 79465] {aka N2DL-3, NKG2DL3, RAET1N}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, MICB (MHC class I polypeptide-related sequence B) [NCBI Gene 4277] {aka PERB11.2}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, ULBP1 (UL16 binding protein 1) [NCBI Gene 80329] {aka N2DL-1, NKG2DL1, RAET1I}, IL2 (interleukin 2) [NCBI Gene 403989], KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, ERVK-25 (endogenous retrovirus group K member 25) [NCBI Gene 100862683] {aka PR, Protease, Proteinase, c11_A}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, SHMT2 (serine hydroxymethyltransferase 2) [NCBI Gene 6472] {aka GLYA, HEL-S-51e, NEDCASB, SHMT, mSHMT}, SLC3A2 (solute carrier family 3 member 2) [NCBI Gene 6520] {aka 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, RAET1E (retinoic acid early transcript 1E) [NCBI Gene 135250] {aka LETAL, N2DL-4, NKG2DL4, RAET1E2, RL-4, ULBP4}
- **Diseases:** pancreatic cancer (MESH:D010190), Cancer (MESH:D009369), NB (MESH:D009447), cytotoxicity (MESH:D064420), glioblastoma (MESH:D005909)
- **Chemicals:** methanol (MESH:D000432), streptomycin (MESH:D013307), carbon (MESH:D002244), iron (MESH:D007501), ethanol (MESH:D000431), glutamate (MESH:D018698), SDS (MESH:D012967), alpha-MEM (MESH:C420642), Lip-1 (MESH:C000595890), cystine (MESH:D003553), penicillin (MESH:D010406), Erastin (MESH:C477224), crystal violet (MESH:D005840), sodium bicarbonate (MESH:D017693), BODIPY  581/591 (-), arginine (MESH:D001120), 2-mercaptoethanol (MESH:D008623), Lipofectamine (MESH:C086724), Lipid (MESH:D008055), cysteine (MESH:D003545), deoxyribonucleosides (MESH:D003853), L-glutamine (MESH:D005973), CO2 (MESH:D002245), GSH (MESH:D005978), Resazurin (MESH:C005843), ROS (MESH:D017382), folate (MESH:D005492), DMSO (MESH:D004121), inositol (MESH:D007294), PVDF (MESH:C024865), PBS (MESH:D007854)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Mycoplasma (genus) [taxon 2093], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 4 C with L
- **Cell lines:** NK-92 — Homo sapiens (Human), Natural killer cell lymphoblastic leukemia/lymphoma, Cancer cell line (CVCL_2142), KELLY — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_2092), pNK — Rattus norvegicus (Rat), Rat large granular lymphocyte leukemia, Cancer cell line (CVCL_F856), SK-N-AS — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0528), SK-N-FI — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_1702)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929413/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929413/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929413/full.md

---
Source: https://tomesphere.com/paper/PMC12929413